Halozyme Therapeutics, Inc. (NASDAQ:HALO) – Jefferies Group reduced their FY2019 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Thursday. Jefferies Group analyst E. Yang now forecasts that the biopharmaceutical company will post earnings of ($0.62) per share for the year, down from their prior estimate of ($0.58). Jefferies Group currently has a “Underperform” rating and a $7.00 target price on the stock. Jefferies Group also issued estimates for Halozyme Therapeutics’ FY2020 earnings at ($0.41) EPS.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.23) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.02. The business had revenue of $33.80 million for the quarter, compared to the consensus estimate of $31.76 million. During the same quarter last year, the business earned ($0.21) EPS. Halozyme Therapeutics’s revenue for the quarter was up 1.2% compared to the same quarter last year.

ILLEGAL ACTIVITY WARNING: “Halozyme Therapeutics, Inc. to Post FY2019 Earnings of ($0.62) Per Share, Jefferies Group Forecasts (HALO)” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark & copyright legislation. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/18/halozyme-therapeutics-inc-to-post-fy2019-earnings-of-0-62-per-share-jefferies-group-forecasts-halo.html.

Several other research firms have also weighed in on HALO. Piper Jaffray Companies set a $20.00 price objective on Halozyme Therapeutics and gave the company a “buy” rating in a research note on Thursday, August 10th. Barclays PLC reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, June 23rd. Zacks Investment Research raised Halozyme Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research note on Friday, August 25th. BidaskClub lowered Halozyme Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, July 1st. Finally, Deutsche Bank AG lifted their price objective on Halozyme Therapeutics to $20.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $16.00.

Halozyme Therapeutics (NASDAQ:HALO) opened at 16.25 on Monday. The company’s market cap is $2.18 billion. Halozyme Therapeutics has a 52-week low of $8.18 and a 52-week high of $16.65. The firm’s 50-day moving average is $12.79 and its 200 day moving average is $13.23.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. lifted its position in Halozyme Therapeutics by 4.8% during the 2nd quarter. BlackRock Inc. now owns 11,595,500 shares of the biopharmaceutical company’s stock worth $148,652,000 after acquiring an additional 532,658 shares in the last quarter. Iridian Asset Management LLC CT lifted its position in Halozyme Therapeutics by 2.0% during the 2nd quarter. Iridian Asset Management LLC CT now owns 10,608,993 shares of the biopharmaceutical company’s stock worth $136,007,000 after acquiring an additional 208,605 shares in the last quarter. Vanguard Group Inc. lifted its position in Halozyme Therapeutics by 9.5% during the 2nd quarter. Vanguard Group Inc. now owns 9,595,212 shares of the biopharmaceutical company’s stock worth $123,010,000 after acquiring an additional 831,654 shares in the last quarter. BB Biotech AG lifted its position in Halozyme Therapeutics by 6.7% during the 2nd quarter. BB Biotech AG now owns 8,265,304 shares of the biopharmaceutical company’s stock worth $105,961,000 after acquiring an additional 515,472 shares in the last quarter. Finally, Senzar Asset Management LLC lifted its position in Halozyme Therapeutics by 17.1% during the 2nd quarter. Senzar Asset Management LLC now owns 4,087,264 shares of the biopharmaceutical company’s stock worth $52,399,000 after acquiring an additional 597,400 shares in the last quarter. 85.06% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company’s segment also includes research and development activities and product sales of Hylenex recombinant.

Earnings History and Estimates for Halozyme Therapeutics (NASDAQ:HALO)

Receive News & Stock Ratings for Halozyme Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics Inc. and related stocks with our FREE daily email newsletter.